WAYNE, N.J., Nov. 20 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals, Inc a leader in diagnostic imaging, announced today that the company has been awarded a three-year contract by MedAssets Supply Chain Systems, one of the nation's largest group purchasing organizations, to provide Magnevist(R) (gadopentetate dimeglumine) Injection contrast media to members of the MedAssets network. MedAssets serves more than 125 health systems, including 2,500 hospitals and 30,000 non-acute care healthcare providers.
This is the first time that Magnevist has been awarded a contract with MedAssets Supply Chain Systems. With this agreement, Magnevist is now on contract or has agreements with nearly all of the major GPOs in the United States.
"We are delighted that MedAssets Supply Chain Systems has awarded a three- year contract to Bayer HealthCare Pharmaceuticals for Magnevist, and we are excited by the potential of this new relationship," said Douglas Stefanelli, Vice President and General Manager, Diagnostic Imaging, Bayer HealthCare Pharmaceuticals. "We look forward to providing the customers of MedAssets and its healthcare providers with both our high quality product and with our high- level of customer support."
The agreement is effective November 1, 2007, includes 5, 10, 15 and 20 mL single-dose vials, 50 and 100 mL pharmacy bulk packages, and 10, 15 and 20 mL pre-filled syringes of Magnevist.
MedAssets partners with healthcare providers to improve their financial strength by implementing integrated spend management and revenue cycle solutions that help control cost, improve margins and cash flow, increase regulatory compliance, and optimize operational efficiency.
ABOUT MAGNEVIST
Magnevist is the leading MRI contrast agent with the broadest range of
FDA approved indications for adult and pediatric patients. For a more
information about approved indications, please visit
| SOURCE Bayer HealthCare Pharmaceuticals, Inc Copyright©2007 PR Newswire. All rights reserved |